Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
7.52
+0.71 (10.43%)
Aug 14, 2025, 2:30 PM - Market open
Mersana Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | - | 107.75 | 174.56 | 128.89 | 177.95 | 255.09 | Upgrade
|
| Short-Term Investments | - | 26.87 | 34.52 | 151.83 | - | - | Upgrade
|
| Cash & Short-Term Investments | 102.29 | 134.62 | 209.08 | 280.71 | 177.95 | 255.09 | Upgrade
|
| Cash Growth | -37.15% | -35.61% | -25.52% | 57.75% | -30.24% | 155.63% | Upgrade
|
| Receivables | - | - | - | 30 | - | - | Upgrade
|
| Prepaid Expenses | - | 2.28 | 4.97 | 8.51 | 10.95 | 3.49 | Upgrade
|
| Total Current Assets | - | 136.9 | 214.06 | 319.22 | 188.9 | 258.58 | Upgrade
|
| Property, Plant & Equipment | - | 6.78 | 11.53 | 14.46 | 14.86 | 12.67 | Upgrade
|
| Other Long-Term Assets | - | 0.98 | 0.48 | 0.66 | 2.36 | 2.15 | Upgrade
|
| Total Assets | - | 144.66 | 226.06 | 334.34 | 206.11 | 273.4 | Upgrade
|
| Accounts Payable | - | 4.33 | 7.32 | 13.95 | 12.32 | 8.34 | Upgrade
|
| Accrued Expenses | - | 18.96 | 20.85 | 43.18 | 28.72 | 16.15 | Upgrade
|
| Current Portion of Long-Term Debt | - | 12.5 | 2.08 | - | - | - | Upgrade
|
| Current Portion of Leases | - | 3.9 | 3.4 | 3.04 | 2.54 | 1.53 | Upgrade
|
| Current Unearned Revenue | - | 22.17 | 28.15 | 30.61 | 3.94 | 3.99 | Upgrade
|
| Other Current Liabilities | - | 0.59 | 1.84 | 0.75 | - | - | Upgrade
|
| Total Current Liabilities | - | 62.46 | 63.64 | 91.53 | 47.52 | 30 | Upgrade
|
| Long-Term Debt | - | 10.95 | 23.15 | 24.93 | 24.63 | 4.98 | Upgrade
|
| Long-Term Leases | - | 1.3 | 5.2 | 8.78 | 11.7 | 10.33 | Upgrade
|
| Long-Term Unearned Revenue | - | 79.46 | 97.17 | 117.04 | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | 0 | - | 0.53 | - | Upgrade
|
| Total Liabilities | - | 154.17 | 189.16 | 242.28 | 84.37 | 45.31 | Upgrade
|
| Common Stock | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | - | 886.02 | 863.24 | 746.89 | 572.21 | 508.5 | Upgrade
|
| Retained Earnings | - | -895.55 | -826.36 | -654.69 | -450.48 | -280.42 | Upgrade
|
| Comprehensive Income & Other | - | 0.01 | 0.01 | -0.15 | - | - | Upgrade
|
| Total Common Equity | -30.87 | -9.51 | 36.9 | 92.06 | 121.74 | 228.09 | Upgrade
|
| Shareholders' Equity | -30.87 | -9.51 | 36.9 | 92.06 | 121.74 | 228.09 | Upgrade
|
| Total Liabilities & Equity | - | 144.66 | 226.06 | 334.34 | 206.11 | 273.4 | Upgrade
|
| Total Debt | 24.62 | 28.65 | 33.83 | 36.75 | 38.86 | 16.84 | Upgrade
|
| Net Cash (Debt) | 77.66 | 105.97 | 175.25 | 243.97 | 139.08 | 238.26 | Upgrade
|
| Net Cash Growth | -40.17% | -39.53% | -28.17% | 75.41% | -41.62% | 159.92% | Upgrade
|
| Net Cash Per Share | 15.68 | 21.62 | 37.73 | 65.12 | 49.26 | 96.87 | Upgrade
|
| Filing Date Shares Outstanding | 4.99 | 4.99 | 4.85 | 4.32 | 3.34 | 2.76 | Upgrade
|
| Total Common Shares Outstanding | 4.99 | 4.63 | 4.83 | 4.21 | 2.95 | 2.75 | Upgrade
|
| Working Capital | - | 74.45 | 150.42 | 227.69 | 141.38 | 228.58 | Upgrade
|
| Book Value Per Share | -6.19 | -2.06 | 7.64 | 21.89 | 41.29 | 82.83 | Upgrade
|
| Tangible Book Value | -30.87 | -9.51 | 36.9 | 92.06 | 121.74 | 228.09 | Upgrade
|
| Tangible Book Value Per Share | -6.19 | -2.06 | 7.64 | 21.89 | 41.29 | 82.83 | Upgrade
|
| Machinery | - | 10.29 | 10.7 | 9.78 | 7.74 | 7.48 | Upgrade
|
| Leasehold Improvements | - | 2.21 | 2.21 | 1.94 | 1.91 | 1.89 | Upgrade
|
Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.